Journal of the Chinese Medical Association
Volume 73, Issue 5 , Pages 262-264, May 2010

Sorafenib in Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation

  • Murat Lekili

      Affiliations

    • Department of Urology, School of Medicine, Celal Bayar University, Manisa, Turkey
    • Corresponding Author InformationCorrespondence to: Dr Murat Lekili, Department of Urology, Celal Bayar University, School of Medicine, Uncubozköy Mevkii, Kat 8, Manisa, Turkey
    • ,
  • Talha Muezzinoglu

      Affiliations

    • Department of Urology, School of Medicine, Celal Bayar University, Manisa, Turkey
    • ,
  • Nalan Nese

      Affiliations

    • Department of Pathology, School of Medicine, Celal Bayar University, Manisa, Turkey
    • ,
  • Gokhan Temeltas

      Affiliations

    • Department of Urology, School of Medicine, Celal Bayar University, Manisa, Turkey

Received 16 April 2009; accepted 3 March 2010.

Article Outline

Targeted therapy in the management of metastatic renal cell cancer has been recently introduced to urology practice. The drugs used for management are used in a very limited number of patients and only for clear cell histology. We present a case where we administered sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, to a patient with metastatic renal cell carcinoma of clear cell histology. We found that our results were different from those of previously reported studies, because sarcomatoid differentiation was evident in a histological examination of this case. There was an excellent response to sorafenib. This case report might provide evidence that antiangiogenic agents may be active in any histological type of renal cell carcinoma. However, there are no available data to demonstrate the duration of response and survival benefit.

Key Words:  metastasis , renal cell cancer , sarcomatoid differentiation , sorafenib

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al  Sorafenib in advanced clear cell renal cell carcinoma . N Engl J Med . 2007;356:125–134
  2. Motzer RJ, Hutson TE, Tomczak P, Michealson MD, Bukolwski RM, Rixe O, et al  Sunitinib versus interferon alfa in metastatic renal cell carcinoma . N Engl J Med . 2007;356:115–124
  3. Kroog GS , Motzer RJ . Systemic therapy for metastatic renal cell carcinoma . Urol Clin N Am . 2008;35:687–701
  4. Sciarra A, Gomez AA, Gentilucci A, Parente U, Salciccia S, Gentile V, et al. Adjuvant therapy with sorafenib in bone metastases bilateral renal carcinoma: a case report . Eur Urol . 2007;52:597–599

PII: S1726-4901(10)70056-3

doi:10.1016/S1726-4901(10)70056-3

Journal of the Chinese Medical Association
Volume 73, Issue 5 , Pages 262-264, May 2010

Article Tools